YH001

DRUG4 trials

Sponsors

Eucure (Beijing) Biopharma Co., Ltd, Tracon Pharmaceuticals Inc.

Conditions

Advanced SarcomaAdvanced Solid TumorAdvanced Solid TumorsMetastatic SarcomaSoft Tissue SarcomaSolid Tumor

Phase 1

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

CompletedNCT04357756

Eucure (Beijing) Biopharma Co., LtdAdvanced Solid Tumor

Start: 2020-04-21End: 2022-10-19Updated: 2023-09-13

A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors

CompletedNCT04699929

Eucure (Beijing) Biopharma Co., LtdAdvanced Solid Tumors

Start: 2021-01-26End: 2022-10-08Updated: 2022-12-12

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

CompletedNCT05176509

Eucure (Beijing) Biopharma Co., LtdSolid Tumor

Start: 2022-04-05End: 2023-08-25Updated: 2025-01-06

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma

Start: 2022-11-14End: 2025-09-30Updated: 2023-09-21

Related Papers

A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-01